Drugs / BCG Bulgaria
BCG Bulgaria
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02709278 | Mar 2016 → May 2019 | tuberculosis | University of Oxford | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Bulgaria | “BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)” NCT02709278 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02709278 ↗ |
| Known as | BCG Danish strain | “Participants were initially enrolled into group 1 (receiving the BCG Danish strain); the trial was subsequently paused because of a worldwide shortage of BCG Danish and, after...” PMID 38621405 ↗ Apr 2024 |
| Known as | BCG SSI | “BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)” NCT02709278 ↗ |
| Known as | InterVax | “BCG Bulgaria (InterVax)” NCT02709278 ↗ |
| Modality | Vaccine | “BCG, the only licensed vaccine” PMID 38621405 ↗ Apr 2024 |
| Route | Inhaled | “BCG challenge administered by the aerosol inhaled route” NCT02709278 ↗ |